We offer quantitative* COVID-19 serology testing through our high-complexity CLIA laboratory.
Our serology tests aid in assessing adaptive immune responses to SARS-CoV-2.
Better Understanding COVID-19We offer tests that measure antibodies against the spike Receptor Binding Domain (RBD) of SARS-CoV-2.
View COVID-19 Serology Test MenuDownload forms to enroll as a provider and order tests.
View Order Forms* Quantitative results are reported for serum and plasma samples;
these are calibrated to the First WHO International Standard for anti-SARS-CoV-2 Immunoglobulin.
Semi-quantitative results are reported for Dried Blood Spot samples.
Billerica, MA, September 29, 2020: ProterixBio, Inc. announced today commercial availability of the SARS-CoV-2 (RBD) IgG Antibody test, a semi-quantitative COVID-19 serology assay. It is being offered as a testing…
Read MoreBillerica, MA, July 1, 2020: ProterixBio, Inc. today announced completing a licensing agreement with the Massachusetts General Hospital for a COVID-19 serology assay. The assay was developed and validated by…
Read More